Don't miss out on the latest business and technology news for chemical engineers, featuring select items in relation to Food, Pharmaceuticals & Bioengineering!
Novartis, Microsoft partner for AI-driven research collaboration
A new partnership was announced by Novartis and Microsoft that could become a transformative venue for drug discovery and research with the use of artificial intelligence. The multi-year agreement will also involve joint research initiatives and co-working environments at the Microsoft Research Lab in the UK, the Novartis Global Service Centre in Ireland and the Novartis Campus in Switzerland.
Researchers exploring options for plastic-eating enzymes
Hitachi, Cambridge Consultants and researchers at other organizations are developing enzymes that can break down plastics such as polyethylene terephthalate, a process that could be used in recycling. Hitachi and Cambridge are exploring solutions that are economically and technologically feasible, says Cambridge's James Hallinan.
35 bioenergy projects to share $75M in Energy Dept. grants
The US Department of Energy announced it had awarded a total of $75 million in grants to 35 bioenergy projects focused on research and development that include enhanced biomass or waste resources divided into 10 topic areas. "The main goal of DOE's bioenergy R&D is to produce affordable biofuels that are compatible with existing fueling infrastructure and vehicles across a range of transportation modes," said Energy Secretary Rick Perry.
FDA clears trial of personalized CD19-specific CAR T-cell therapy
The FDA gave its approval to proceed with an early-stage trial of Ziopharm Oncology's chimeric antigen receptor T-cell therapy as a treatment for relapsed CD19+ leukemias and lymphomas. The study will include up to 24 patients who have experienced relapses following allogeneic bone marrow transplantation, and the cells will be produced using a rapid personalized manufacture technique.
Descovy approved as 2nd PrEP drug for HIV, with exclusions
Gilead Sciences' Descovy, or emtricitabine and tenofovir alafenamide, has gained FDA approval as the second option for pre-exposure HIV prophylaxis. The approval indicates the drug can be used to prevent the disease in transgender women and HIV-negative men who have sex with men but does not cover cisgender women.
Positive results reported by Trovagene on onvansertib midstage trial
Data from Trovagene's Phase Ib/II clinical trial assessing onvansertib in patients with relapsed or refractory acute myeloid leukemia showed the drug was safe and effective, according to a presentation made at the 2019 European Society for Medical Oncology Conference. Trovagene plans to enroll 32 patients with AML in the midstage trial to evaluate onvansertib combined with decitabine in participants who complete at least a single treatment cycle.
- Log in to post comments